Veranstaltungen

5th Innovative Approaches for the Identification of Antiviral Agents Summer School (IAAASS)

Datum
September 22, 2021 - September 24, 2021

Zeit
Ganztägig

Veranstaltungsort




Ort:
virtual meeting

Beschreibung:

As every other year, together with Cristina Parolin and some American colleagues, we are organizing the 5th Innovative Approaches for the Identification of Antiviral Agents Summer School (IAAASS).

This year the Summer School will take place from September 22nd-24th, 2021 and, given the ongoing COVID-19 pandemic, will be held with a virtual format (hopefully this year only).

This Summer School is focused on all stages of antiviral drug development from target identification and screening to structural studies and medicinal chemistry. Our primary goal is enabling young scientists (Ph.D. students and post-docs) to meet and interact with internationally recognized experts. Trainees will be able to present current research, share ideas for future research, and have plenty of opportunities for informal career discussion with industry and academic leaders.

Each session of the Summer School will have a plenary talk, 2-3 short talks from leaders in the field, and multiple 15-minute talks selected from abstracts submitted by student and postdoctoral participants. Please see the IAAASS website for up-to-date information: http://people.unica.it/iaaass/

To enroll and register for the 5th Summer School, participants are encouraged to send an abstract (please see the format on https://people.unica.it/iaaass/registration/) and Curriculum Vitae to iaaass@unica.it.

 

For more details, please see https://people.unica.it/iaaass/registration/ , or send an e-mail to iaaass@unica.it or to Dr. Maria Paola Pisano: mp.pisano@unica.it

Accepted participants will then be invited to pay a €50 fee to complete the registration process.

The deadline for receiving all application materials is July 31st, 2021.

This Summer School will showcase many different areas of virology research and drug discovery including cutting-edge work on SARS-CoV-2.